Dr. Abedin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6800 Wisconsin Ave
#1125
Chevy Chase, MD 20815Phone+1 240-200-4115Fax+1 646-349-7620
Summary
- Physician scientist and healthcare consultant with 10+ year experience in exploratory research and clinical drug development. Shaad is a practicing physician who is board certified in internal medicine, hematology & medical oncology, with a diverse skill set of preclinical lab based experience, Phase 1 to 3 Trial design & strategy, global execution and approvals.
Education & Training
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2009 - 2012
- University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2006 - 2009
- Dow University of Health SciencesClass of 2004
Certifications & Licensure
- MD State Medical License 2012 - 2026
- VA State Medical License 2012 - 2026
- DC State Medical License 2013 - 2024
- FL State Medical License 2020 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow American College of Physicians, 2015
- Young Investigator Award American Society of Clinical Oncology, 2012
- CMS Meaningful Use Stage 1 Certification SuiteMed EMR, Fox Meadows Software, 2013
Publications & Presentations
PubMed
- 157 citationsPrognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint BlockadeQu Zhang, Jia Luo, Song Wu, Han Si, Chen Gao
Cancer Discovery. 2020-08-14 - 345 citationsOverall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul C. Nathan, Jessica C. Hassel, Piotr Rutkowski, Jean-François Baurain, Marcus O. Butler
The New England Journal of Medicine. 2021-09-23 - 22 citationsResistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cell lung cancer patients and is reversed by STAT3...Nabendu Pore, Song Wu, Nathan Standifer, Maria Jure-Kunkel, Melissa de los Reyes
Cancer Discovery. 2021-07-06
Professional Memberships
- Fellow
- Member
- Member
Other Languages
- Hindi, Punjabi, Urdu
External Links
- Websitehttp://www.fda.gov/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: